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cAMP-dependent protein kinase (PKAc) is a pivotal signaling
protein in eukaryotic cells. PKAc has two well-characterized
regulatory subunit proteins, RI and RII (each having  and 
isoforms), which keep the PKAc catalytic subunit in a catalyti-
cally inactive state until activation by cAMP. Previous reports
showed that the RI regulatory subunit is phosphorylated by
cGMP-dependent protein kinase (PKG) in vitro, whereupon
phosphorylated RI no longer inhibits PKAc at normal (1:1)
stoichiometric ratios. However, the significance of this phos-
phorylation as a mechanism for activating type I PKA holoen-
zymes has not been fully explored, especially in cellular systems.
In this study, we further examined the potential of RI phos-
phorylation to regulate physiologically relevant “desensitiza-
tion” of PKAc activity. First, the serine 101 site of RI was vali-
dated as a target of PKGI phosphorylation both in vitro and in
cells. Analysis of a phosphomimetic substitution in RI (S101E)
showed that modification of this site increases PKAc activity in
vitro and in cells, even without cAMP stimulation. Numerous
techniques were used to show that although Ser101 variants of
RI can bind PKAc, the modified linker region of the S101E
mutant has a significantly reducedaffinity for thePKAcactive site.
These findings suggest that RI phosphorylation may be a novel
mechanism to circumvent the requirement of cAMP stimulus to
activate type I PKA in cells. We have thus proposed a model to
explain how PKG phosphorylation of RI creates a “sensitized
intermediate” state that is in effect primed to triggerPKAcactivity.
cAMP-dependent protein kinase (PKAc; with , , and 
isoforms)2 is a pivotal cell signaling protein in eukaryotes (1–4).
The catalytic activity of PKAc is in part controlled by four func-
tionally non-redundant regulatory subunit proteins (RI, RI,
RII, and RII) (5–8), which bind PKAc in tetrameric “holoen-
zyme” complexes to maintain kinase inactivity until stimula-
tion with cAMP (1, 9). The structural assembly of PKA holoen-
zymes and allosteric activation mechanism triggered by cAMP
binding to R-subunits is well-understood (9–15). However,
unique biochemical features of RI may serve to activate
PKAc via non-canonical, cAMP-independent mechanisms.
The linker–hinge region of PKA regulatory subunit proteins
contains the autoinhibitory motif that allows for selective inhi-
bition of PKAc at the kinase active site; however, this inhibitor
sequence (IS) differs significantly between RI and RII (11, 16).
Although RII subunits have a PKA consensus phosphorylation
sequence (RRXS) that is phosphorylated by PKAc, RI subunits
have a “pseudosubstrate” IS (RRX(A/G)) that is unable to be
phosphorylated by PKAc; therefore, substrate competition is
required to trigger full PKA holoenzyme dissociation (17).
Additionally, RI subunit has three serine residues in the linker
region that are putative phosphorylation sites: Ser77, Ser83, and
Ser101 (Fig. 1A) (18–20). Previously, the Ser101 residue (P 2 to
the pseudosubstrate IS) was shown to be an in vitro substrate of
cGMP-dependent protein kinase (PKG) (21, 22). Given the
nature of the in vitro methodology used previously to assess
phosphorylation of this site, as well as the lack of identity of a
well-defined PKG consensus phosphorylation sequence, the
physiological relevance of this putative phosphorylation site
remains uncharacterized. To expand upon this work, experi-
ments were aimed at validating in vitro studies with purified
recombinant proteins and determining whether this unique
mechanism of PKA activation happens in cell culture models.
Recent structural information acquired in the last 10–15
years concerning the nature of binding between PKAc and RI
allows for some conjecture about how modification of Ser101
might lead to changes in type I PKA activity. The protein struc-
ture of the RI–PKAc heterodimer was solved by X-ray crystal-
lography techniques by Kim et al. (12), and this structure
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showed how the linker region of RI binds the active site cleft of
PKAc. The IS makes direct contacts with residues from both
the N-lobe and C-lobe of PKAc, whereas the CNB-A domain
binds distally to the C-lobe. Because of the pseudosubstrate
nature of the IS in RI, the high affinity binding of this motif to
PKAc (in complex with ATP and two magnesium ions,
Mg2ATP) presents a kinetic barrier for activation, whereas this
is not critical for RII subunits capable of phosphorylation by
PKAc (16, 23). The binding affinity of RI and PKAc in the
presence of Mg2ATP is 0.1 nM versus 200 nM in the absence of
nucleotide (24). ATP also binds with an affinity of 60 nM in the
RI holoenzyme, whereas the Km/Kd is 25 M for the free pro-
tein. This gives a rationale for why modification of Ser101 could
possibly perturb the binding interaction of the linker region of
RI to PKAc.
A close-up view of this interfacial region helps to illustrate
the importance of this residue in maintaining proper binding
interactions with PKAc (Fig. 1B). Upon analysis of polar inter-
actions in this region, one can see that the hydroxyl moiety of
Ser101 makes hydrogen bonds with residues from the C-helix
of PKAc (particularly residues Gln84 and His87). It is inferred
that introduction of a phosphate group at this position will
introduce steric hindrance that will likely alter the interaction
of these residues. Furthermore, the interaction of Ser101 with
Gln84 and His87 facilitates a hydrogen-bond network near the
activation-loop phosphorylation site Thr197 in PKAc. Thus, we
can further postulate that phosphorylation of Ser101 will also
bring about a negative charge–charge repulsion effect caused
by the juxtaposition of two phosphate groups within this bind-
ing interface. These effects in combination would lend to open-
Figure1.A, cartoondiagramofRIdomain layout,with emphasis on the linker region sequenceandphosphorylation sites Ser77, Ser83, andSer101. RIdomains
from the N terminus to the C terminus were as follows: dimerization/docking (D/D) domain, the pseudosubstrate inhibitory site (IS; sequence is shown in red
underlined text), and tandemCNBdomains. The presumed kinases for each putative phosphorylation site are listed below. The PKGphosphorylation site Ser101
is indicated by a red asterisk. B, PyMOL structural representation of the RI–PKAc heterodimer complex (Protein Data Bank code 2qcs), focusing on the binding
interface between the active site of PKAc and the linker region IS of RI (light-gray cartoon, PKAc N-lobe; olive-green surface, PKAc C-lobe; teal cartoon, RI CNB
domains; red cartoonwith sticks, RI linker region containing the IS to PKAc). The serine residueof interest in RI (Ser101, red) is depicted alongwith other critical
residues at this binding interface, including 1) the pseudosubstrate alanine (Ala99) and p 1 residue (Ile100) from the RI linker region; 2) two residues from the
C-helix of PKAc (Gln84 and His87) that form direct hydrogen bonds with the hydroxyl group of serine 101; and 3) activation loop phosphorylation site
(Thr(P)197) and its neighboring residues in PKAc (Arg165, Arg189, and Ser195). Hydrogen bonds are depicted as dashed lines.
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ing of the active site cleft of PKAc. Taking these observations
under consideration, we hypothesized that phosphorylation of
Ser101 by PKG would promote enhanced PKAc activity by
removing the additional requirement of substrate competition
in RI holoenzyme activation. Finding evidence of direct
PKG–PKA cross-talk in the context of cellular signaling
would aid our understanding of how these two related path-
ways could regulate physiologically relevant systems where
both proteins are expressed (i.e. smooth muscle and cardiac
tissues) (25, 26).
Results
PKGI phosphorylates RI at serine 101 both in vitro and in
cells
To extend previous reports demonstrating that PKA RI
couldbephosphorylatedbyPKGI,weperformed in vitrophos-
phorylation reactions using purified recombinant bovine RI
(bRI)–PKAc holoenzyme and PKGI. The reactions con-
tained [-32P]ATP, and phosphate incorporation was deter-
mined by autoradiography. We observed robust phosphoryla-
tion of bRI only in the presence of PKGI (Fig. 2A, compare
lanes 5–8with lanes 1–4; quantification of data in Fig. 2B). RI
was phosphorylated by PKGI to a similar extent in the absence
and presence of cyclic nucleotides (lanes 5–8). These results
are a bit unexpected, because cyclic nucleotide free and cAMP-
bound PKGI should not be as active as the cGMP-bound
kinase. However, under the conditions used, it is likely that
PKGI activity was driven by PKGI autophosphorylation and
was cyclic nucleotide–independent. We originally reasoned
that cAMP would disassociate bRI from PKAc and thus pro-
vide easier access for PKGI to phosphorylate Ser101; however,
although there was a trend toward increased RI phosphory-
lation in the presence of cAMP, the difference did not reach
significance (compare lane 5 with 7 and 6 with 8). Thus, it
appears that holoenzyme association/dissociation has no effect
on PKGI’s access to the phosphorylation site.
Next, we examinedwhether PKGI could phosphorylate RI
in intact cells. HEK293T cells were transfected with expression
vectors for PKGI and FLAG-tagged WT or S101A-mutant
human R. The cells were labeled with [32P]orthophosphate,
and the differences betweenWT and S101A-mutant RI phos-
phorylation were compared in the presence or absence of
PKGI, as well as with and without 2-h stimulus with 8-CPT-
cGMP (a membrane-permeable analog of cGMP). In cells
transfected withWTRI alone, we observed a small amount of
basal RI phosphorylation, which was slightly increased by
Figure 2. PKGI phosphorylates RI in vitro and in cells. A, the upper panel shows autoradiography of in vitro PKG phosphorylation reactions conducted
with purified recombinant bovine RI in complex with PKAc (holoenzyme). For all reactions, 0.6 g of holoenzyme was incubated with or without purified
PKGI in the presence of 1 M of the indicated cyclic nucleotides. The lower panel shows equal loading via an anti-RI immunoblot. B, densiometric quantifi-
cation of three experiments performed as described in A, expressed as means S.D. Statistical significance is indicated by planned comparisons. C, autora-
diography and immunoblot analysis of phosphorylation reactions performed in HEK293T cells overexpressing FLAG-tagged versions of either wildtype or
S101A mutant R protein, with and without the presence of PKGI and/or 2 h of cGMP stimulus (upper panel). The lower panel shows equal expression and
isolation of FLAG-tagged RI proteins via an anti-FLAG immunoblot. D, densiometric quantification of three experiments performed as described in C,
expressedasmeansS.D. Statistical significance is indicatedbyplannedcomparisons. E, theupper panel showsautoradiographyofphosphorylation reactions
performed inHEK293T cells overexpressingFLAG-taggedconstructs of eitherWTor serine77and serine83mutant versionsof RI (S77/83A). All reactionswere
performedwith overexpressed PKGIwith or without 2 h of 8-CPT-cGMP stimulus. The lower panel is an immunoblot using anti-FLAG antibodies as a loading
control.
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treatment with 8-CPT-cGMP (Fig. 2C, compare lanes 1 and 2;
quantification of data in Fig. 2D). In cells co-transfected with
PKGI, treatment with 8-CPT-cGMP induced a much higher
level of RI phosphorylation, which was dramatically reduced
in cells transfected with PKGI and S101A-mutant RI (Fig.
2C, compare lane 2 with lane 6 and lane 6 with lane 8). The
lower panel of Fig. 2C is an immunoblot using anti-FLAG anti-
bodies, showing an equal expression of transfected FLAG-
tagged RI in all samples tested. Our results indicate that RI
Ser101 is a specific phosphorylation target of PKGI in cells.
In these cell-based experiments, the faint phosphorylation
signal observed for RI in cells expressing S101A-mutant RI
indicates the presence of other phosphorylation sites that are
targeted in cells. To address this, two other putative phosphor-
ylation sites within RI protein, namely Ser77 and Ser83, were
investigated (Fig. 2E). These two sites have been shown to be
phosphorylated in human heart tissues in the context of ische-
mic heart disease (20) and thus may contribute to the back-
ground signal in our phosphorylation assays. Phosphorylation
reactions were performed in HEK293T cells overexpressing
FLAG-tagged constructs of either WT or a mutant version of
R protein with both Ser77 and Ser83 mutated to alanine. All
reactions were conducted with overexpressed PKGI either
with or without 2 h of cGMP stimulus. In cells overexpressing
WT protein, low levels of RI phosphorylation in cells with-
out cGMP stimulus were observed as seen in previous exper-
iments. However, cells expressing the S77A/S83A double
mutation of RI did not yield phosphorylation signal with-
out cGMP stimulus, indicating that all background signal
observed in non-stimulated samples is due to extraneous
in-cell phosphorylation of these two particular sites. As
before, immunoblots using anti-FLAG antibodies were per-
formed to show equal expression of RI. These initial phos-
phorylation experiments performed under both in vitro and
in-cell conditions have shown that serine 101 in RI is
indeed a bona fide phosphorylation target of PKGI in mam-
malian cells.
Mutation at serine 101 in RI induces PKAc activity without
cAMP stimulus in vitro and in cells
Asmentionedintheintroduction,wehypothesizedthatphos-
phorylation of Ser101 would serve to increase PKAc activity in
cells. Therefore, we developed mutations at this site in RI, via
site-directed mutagenesis of the serine to either a glutamate
residue (S101E) or an alanine residue (S101A), to test whether
this modification will weaken IS binding to the active site of
PKAc and thus allow the competition of substrates to bind and
be phosphorylated. After generating S101E and S101A mutant
constructs for recombinant protein purification (full-length
bovine RI (1–379) in pRSET vector) and S101E mutant
for mammalian cell transfection (full-length human RI
(1–379) in pcDNA3.1 vector), components of the PepTag
phosphorylation assay were used to assess differences in
PKAc activation for wildtype versus mutant protein under
both in vitro and in-cell conditions. Under in vitro condi-
tions, WT RImaintains PKAc in an inhibited state without
cAMP stimulus; however, both S101E and S101A mutants
display high PKAc activity under basal (cAMP-free) condi-
tions (Fig. 3, A and B). Increasing S101E protein concentra-
tion from 2, 5, and 10 the relative stoichiometry of WT
protein had no effect on inhibiting the observed high basal
PKAc activity (Fig. 3C).
For in-cell analysis of PKAc activity, WT and S101E-mutant
human RI were overexpressed in MEF RI/ cells (mouse
embryonic fibroblasts with a genetic knockout of PRKAR1).
The RI/ cell line allows for a null background to compare
the addition of exogenous RI overexpression. The relative
degree of PKAc phosphorylation activity was compared
between non-transfected cells (control RI/) and cells over-
expressing either WT or S101E-mutant human RI (Fig. 3, D
and E). Control cells displayed high substrate phosphorylation
under non-stimulated conditions, thus serving as a positive
control for PKAc activity and also confirming earlier observa-
tions that in the absence of RI, PKA activity is not well-regu-
lated even though other R-subunit isoforms are present. In
close corroboration with in vitro data, overexpression of WT
RI in cells inhibited PKAc activity in the absence of Fsk/IBMX.
In contrast to WT, cells expressing the S101E mutant
showed high activity without cAMP stimulus, similarly as
observed under in vitro conditions. We also conducted
immunoblot analysis of RI and PKAc expression in MEF
RI/ lysates for the corresponding activity assay samples
examined (Fig. 3,D and F). Two major trends were observed:
1) in WT cells, the level of RI was slightly decreased upon
Fsk/IBMX stimulation; and 2) RI expression appeared to be
slightly higher in S101E cells as compared with cells express-
ing WT RI (but only significant when comparing WT vehi-
cle to S101E Fsk/IBMX samples). The competitive nature of
the phosphorylation reactions employed suggests that the IS
of RI(S101E) must have a lowered affinity for the PKAc
active site cleft; otherwise the PKA substrate would not be
able to bind effectively to allow for phosphotransfer activity
of PKAc.
Two explanations are possible for the aforementioned
results. One possibility is that the RI(S101E) mutant is simply
unable to form a complex with PKAc; alternatively, the mutant
RI protein may still distally bind PKAc (via the R-subunit
CNBs domains), even though the modified sequence in the IS
region is loosely anchored to the PKAc active site cleft. There-
fore, several techniques were explored to evaluate the relative
capacity of S101E and S101A mutants of RI to form
holoenzyme.
Ser101mutant variants of RI pulldown PKAc fromHEK293T
cell lysates via co-immunoprecipitation (co-IP)
To demonstrate that the Ser101 mutants of RI can form
holoenzyme complexes in cells, FLAG-tagged versions of
human RI were overexpressed in HEK29T cells, whereupon
we assessed whether the S101A and S101E mutant variants of
RI were able to pull down overexpressed HA-tagged PKAc
protein from cell lysates via co-immunoprecipitation. In this
experiment, immunoblotting for the presence of HA-tagged
protein in anti-FLAG IP samples can be used to qualitatively
determine the state of holoenzyme complex formation in
cells. We observed HA-tagged PKAc in the immunoprecipi-
tate of all RI proteins tested (WT, S101A, and S101E), sig-
RIa Ser101 phosphorylation by PKG activates PKAc in cells
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nifying that these mutations do not influence the formation
of heterodimer complexes between PKAc to RI (Fig. 4A).
Furthermore, co-immunoprecipitation of PKAc was also
possible in the presence of excess substrate (Kemptide), indi-
cating that excess substrate does not promote holoenzyme
dissociation (Fig. 4B).
Figure 3. Mutation of bovine RI at serine 101 induces PKAc activity without cAMP stimulus in vitro. A, analysis of in vitro PKAc kinase activity using the
PepTag activity assay kit, comparing the inhibitory capacity of either WT, phosphomimetic mutant (S101E), or alanine mutant (S101A) variants of purified
bovine RI protein (n 3). B, densiometric quantification of three experiments performed as described in A, expressed asmeans S.D. Statistical significance
is indicated as compared with RI(WT) without cAMP. **, p 0.001; ***, p 0.0001. C, qualitative analysis of in vitro PKAc kinase activity using the PepTag
activity assay kit, comparing the inhibitory capacity of eitherWTor phosphomimeticmutant (S101E) variants of purified bovine RIprotein. In this experiment,
full-length RI S101Edimer proteinwas added indoses of progressively highermolar stoichiometry as comparedwith PKAcprotein. Lane 1, noprotein control;
lanes 2–12, 200 nM PKAc; lanes 3 and 4, 120 nM WT dimer; lanes 5 and 6, 120 nM S101E dimer; lanes 7 and 8, 240 nM S101E dimer; lanes 9 and 10, 480 nM S101E
dimer; lanes 11 and 12, 1.2M S101E dimer (n 1). D, analysis of PKAc kinase activity using the PepTag activity assay kit, comparingWT or phosphomimetic
mutant (S101E) variants of humanRIoverexpressed inMEFRI/ cells (mouse embryonic fibroblastswith genetic knockout of PRKAR1). To stimulate cAMP
production in these cells, Fsk/IBMX (10 and 100 M) were added for 10 min prior to cell lysis and subsequent activity assay (n  3). The lower panels are
immunoblots of RI, PKAc, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) loading control for the given treatment conditions. E, densiometric
quantificationof three activity assay experiments performedas described inD, expressed asmeans S.D. Statistical significance is indicated as comparedwith
WT without Fsk/IBMX. *, p 0.05. F, densiometric quantification of three immunoblot experiments performed as described in D, expressed as means S.D.
Statistical significance is indicated as compared with WT without Fsk/IBMX. *, p 0.05. Ctrl, control.
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Protein-fragment complementation assay (PCA) shows Ser101
mutants form cAMP-sensitive complexes in cells
To further confirm that mutant RI forms stable holoen-
zyme complex in cells, a bioluminescent PCA (developed by
Stefan and co-workers. (27); see “Experimental procedures”)
was implemented. This assay uses differential tagging of PKA
regulatory and catalytic subunit proteins with fragments of
Renilla luciferase (RLuc) to create a “split-reporter” system that
can be used tomonitor R–C complex formation as a function of
luciferase-fragment complementation. Upon cellular overex-
pression of RLuc-tagged versions of PKAc and either wildtype,
S101A, or S101E variants of RI, the relative degree of RI–
PKAc protein–protein interaction can be measured in intact
cells. Moreover, PKA holoenzyme dissociation can be mea-
sured by luminescence signal decrease upon cellular stimula-
tionwith isoproterenol (a-adrenergic receptor agonist known
to stimulate cAMP production in cells). We observed that
Ser101mutants of RI still displayed a similar degree of complex
formation as compared with wildtype in non-stimulated cells
(Fig. 5). Furthermore, bioluminescence signal was diminished
upon addition of isoproterenol in all protein constructs tested,
thus showing that the Ser101 mutant variants of RI–PKAc
complexes are still sensitive cAMP and thus allow for holoen-
zyme dissociation under stimulatory conditions.
cAMP response of bRI proteins shows high inhibitor binding
for S101E, but not S101Amutant
For a more quantitative understanding of PKAc binding
affinities for wildtype and mutant RI subunits in vitro, we uti-
lized the ligand-regulated competition (LiReC) fluorescence
polarization assay (see “Experimental procedures”) (28). This
competitive inhibitor-binding assay is used to detect the rela-
tive fluorescence polarization of FAM-IP20, a fluorescein-con-
jugated PKA inhibitor peptide that is derived from the heat
stable protein kinase inhibitor. In the LiReC assay, the relative
increase of the fluorescence polarization signalmeasured as the
IP20 probe binds PKAc is indicative of the decrease in anisotro-
pic tumbling of the immobilized inhibitor. First, a cAMP
response assay was performed to compare FAM-IP20 binding
to PKAc in the presence of either the WT, S101A, and S101E
versions of RI (Fig. 6). Whereas the S101A mutant behaved
similarly as WT protein, the S101E mutant displayed signifi-
cantly higher levels of FAM-IP20 binding in the absence of
cAMP. In this instance, the S101E and S101A mutants showed
lower EC50 values as compared with WT, yet Hill slope values
for both mutants were not significantly changed.
R-subunit inhibition response assay shows S101E binds PKAc
with lower relative affinity
To more conclusively determine whether RI(S101E) with
itsmodified linker region can functionally bind PKAc, the assay
was modified to assess the inhibitory capacity for the RI sub-
unit in the presence of a constant concentration of PKAc (10
nM) and in the absence of cAMP (Fig. 7).WT, S101A, and S101E
proteinswere compared to discern any differences in formation
of holoenzyme complexes for these serine 101 mutants. We
observed that significantly higher levels of S101E mutant were
required to out-compete FAM-IP20 for binding to PKAc
(IC50S101E 212.5 nM 1.55). In contrast, S101A behaved very
similar to WT RI (IC50WT 4.5 nM 1.05; IC50S101A 5.05
nM  1.08), indicating that both proteins have an affinity for
PKAc of less than 10 nM, which is the concentration of PKAc in
the assay. These data suggest that the presence of the glutamic
acid residue specifically and significantly affects the affinity of
the RI subunit to the PKAc active site, whereas the more
conservative alanine substitution can function similar to
unmodified wildtype protein at 10 nM concentrations. Thus,
these experiments were able to illustrate that RI(S101E)
can functionally bind PKAc to out-compete FAM-IP20, but
Figure4.Ser101mutantvariantsofRIpulldownPKAc fromHEK293Tcell
lysates via co-IP. Immunoblot analysis of co-IP reactions from HEK29T cell
lysates, comparing cells overexpressingFLAG-taggedversionsof eitherWTor
serine 101 mutant variants (S101A and S101E) of RI, was performed. The
presence of HA-tagged PKAc protein (C) was examined in co-IP samples to
qualitatively determine the state of RI–PKAc complex formation in cells. InA,
co-IP experiments were performed on untreated lysates, whereas in B, co-IP
experiments were performed in the presence of 500 M Kemptide substrate
peptide. Both S101A and S101E mutants maintained binding to PKAc under
all conditions tested, indicating that these mutations do not influence com-
plex formation in cells. I.P., immunoprecipitation.
Figure 5. PCA shows Ser101 mutants form cAMP-sensitive complexes in
cells. PCA (see “Experimental procedures”) was performed to measure RI–
PKAc protein association in isoproterenol-stimulated HEK293T cells, compar-
ingWT tomutant RI (S101A and S101E). In this assay, increased biolumines-
cence signal indicates complementation of the luciferase “split reporter”
caused by protein–protein interactionmediated by holoenzyme association.
Moreover, PKA holoenzyme dissociation ismeasured by luminescence signal
(relative light units) decrease upon cellular stimulation with isoproterenol (a
-adrenergic receptor agonist known to stimulate cAMP production in cells).
Shown is a representative of n  3 independent experiments;  standard
deviation from triplicates.
RIa Ser101 phosphorylation by PKG activates PKAc in cells
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the relative inhibitory equilibrium constant was approxi-
mately 2 orders of magnitude higher compared with the
wildtype RI control.
Discussion
To summarize the work presented here, we have revisited
and additionally built upon a former concept within the field of
protein kinase signaling, which highlights a potential cross-talk
mechanism between the key contributors of cyclic nucleotide
signaling in eukaryotic cells (PKA and PKG). Our evidence has
validated that Ser101 in RI is a target of PKG both in vitro and
incells, and furthermoreweshowed that introductionof aphos-
phorylationmodification (or phosphomimeticmutation) at the
serine 101 site in RI leads to a state of heightened PKAc activ-
ity while still maintaining a RI–PKAc complex. These data
significantly shift the paradigm regarding our understanding of
Type I PKA signaling, in that modification of the RI linker
region can serve to circumvent previously described kinetic re-
strictions of holoenzyme dissociation and thus trigger what we
denote as “desensitized” PKAc activity. We have thus created a
revised model of RI holoenzyme activation to better illustrate
how the effect of PKGphosphorylation could lead to significant
changes in the equilibrium of RI–PKAc association and dis-
sociation (Fig. 8). In this model, modification of RI leads a
“sensitized intermediate” state of the RI holoenzyme that is
capable of phosphotransfer activity because of the lack of linker
region accessibility at the PKAc active site. The addition of
physiological levels of cAMP thus can trigger rapid dissociation
of the holoenzyme complex, therefore creating a “desensitized”
state of activity because of the reduced affinity of the modified
Figure 7. R-subunit inhibition response assay shows that S101E binds
PKAcwith lower relativeaffinity. LiReC fluorescencepolarization assay (see
“Experimental procedures”) compared inhibitory capacity of regulatory sub-
unit protein between WT (black), S101E mutant (red), and S101A mutant
(blue) forms of bRI. A, graph of fluorescence polarization data reported in
millipolarization units (mP). B, table of IC50 values and Hill slope. (Each condi-
tion was performed in quadruplicate, n  4; error bars and table data are
representative of S.E.).
Figure 6. cAMP response of bRI proteins shows high inhibitor bind-
ing for S101E, but not S101A mutant. A LiReC fluorescence polariza-
tion assay (see “Experimental procedures”) compared cAMP response
between WT (black), S101E mutant (red), and S101A mutants (blue) forms
of bRI. A, graph of fluorescence polarization data reported in millipolar-
ization units (mP). B, table of EC50 values and Hill slope. (Each condition
was performed in quadruplicate, n  4; error bars and table data are rep-
resentative of  S.E.).
Figure 8. PKG phosphorylationmodel of type I PKA activation.A cartoon
diagramof amodified, three-statemodel of type I PKAholoenzymeactivation
based on RI phosphorylation by PKG is shown. Our model illustrates that
type I holoenzyme may not transition directly from an inactive holoenzyme-
complex state to a completely dissociated and active state. Instead, our data
suggest that phosphorylation of serine 101 in RI lowers the affinity between
the IS of RI and the active site of PKAc, thus leading to a “sensitized interme-
diate” state that displays PKAc catalytic activity while maintaining a holoen-
zyme complex configuration. This intermediatewould then respond to phys-
iological levels of cAMP towarda “desensitized” active stateof thedissociated
holoenzyme complex. Our model also denotes the potential for reversibility
of linker region phosphorylation by protein phosphatases (PP).
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RI to reassociate with PKAc. Although this study focused
uponPKGphosphorylation of Ser101 inRI, our supplementary
investigation of alternative phosphorylation sites in the linker
region portion of the protein (i.e. Ser77 and Ser83) has further
highlighted the potential significance of linker regionmodifica-
tion as a regulatory mechanism for type I PKA in cells. Because
these sites are differentially phosphorylated in heart tissues
with and without onset of heart failure (20), it is possible that
these linker region phosphorylation sites in RI are specifically
involved in regulating response to stress in the context of car-
diac disease. Further investigation is also required to address
the presumed role of protein phosphatases in allowing revers-
ibility of phosphorylation at these linker region sites.
In terms of chemical equilibrium, we propose that modified
RI (i.e. the sensitized intermediate) has a significant (nearly 2
orders of magnitude) decrease in binding affinity to PKAc as
compared with the 0.1 nM Kd of the inactive holoenzyme. This
assertion could very well explain discrepancies observed in
related scientific literature, where it has been shown that eleva-
tion of cAMP under physiological conditions may not be suffi-
cient to explain how PKA is activated upon stimulatory signal-
ing in the cell (29). However, further examination is required to
determine the exact nature of binding in the “sensitized inter-
mediate” protein complex, with particular regard to 1) pseudo-
substrate binding/accessibility to the active site cleft of PKAc,
and 2) effects upon allosteric interactions in the modified
holoenzyme. In future studies, surface plasmon resonance
methods will be used to quantitatively determine the binding
affinity of Ser101 mutants for PKAc. Utilization of alternative
biophysical methodologies such as hydrogen/deuterium
exchange mass spectrometry could also help to better ex-
plore the relative degree of conformational dynamics for
WT and S101E proteins binding to PKAc by quantifying the
degree of solvent exposure upon differing timescales of
protein–protein interactions.
Although this study provides additional biochemical charac-
terization of PKG phosphorylation of Ser101 in RI in a cellular
overexpression system, a final goal for this work is to assess the
significance of this mechanism within in vivo systems. Because
both PKG and PKA signaling play critical roles within cardiac
and smooth muscle cell physiology (26, 30, 31), our ongoing
research is aimed at detecting endogenous phosphorylation of
RI in differentiated muscle cell types, either treated with or
without stimulus to drive PKG activity. Along this line of inves-
tigation, determining the role of oxidative stress signaling in the
activation of this cross-talk mechanism will be of particular
importance, because reactive nitrogen/oxygen signaling has
been shown to result in alterations of heart physiology as man-
ifested through both PKA and PKG (32–34). Given that both
PKG and PKA have been implicated as targets in disease con-
ditions such as dilated cardiomyopathy (35–37), heart failure
with preserved ejection fractions (38, 39), and ischemia reper-
fusion injury (40, 41), characterization of RI phosphorylation
within endogenous tissues may further bolster the significance
of this mechanism within the context of clinically relevant car-
diovascular diseases.
Experimental procedures
Materials
Antibodies for PKAc and RIa were fromBDBiosciences (San
Jose, CA); antibodies for glyceraldehyde-3-phosphate dehydro-
genase were from Santa Cruz Biotechnology (Dallas, TX).
Anti-HA and anti-species secondary antibodies were obtained
from Santa Cruz Biotechnology. Other antibodies, chemicals,
and reagents were obtained from Sigma unless otherwise
stated.
Recombinant DNA and site-directedmutagenesis
Constructs of full-length human RIa gene (hRIa 1–379)
incorporated into the pCDNA3.3 mammalian expression vec-
tor were used for cellular transfection experiments in MEFs.
Point mutations (hRIa[S101A] and hRIa[S101E]) were intro-
duced by site-directed mutagenesis via QuikChange PCR as
per the manufacturer’s instructions (Stratagene, La Jolla, CA).
The same genetic material was also incorporated into pRSET-
Xa3 vector for bacterial recombinant protein expression.
Point mutations (bRIa[S101A] and bRIa[S101E]) were intro-
duced into both constructs by site-directed mutagenesis via
QuikChange PCR as per the manufacturer’s instructions
(Stratagene). FLAG-tagged RI was constructed by PCR using
an untagged RI vector as a template. The PCR product was
digested and inserted into the pFLAG-D expression vector. The
S101A and S101E mutant RI constructs were generated using
overlapping extension PCR. All constructs that went through a
PCR step were sequenced to ensure that the expected coding
sequence was present.
Expression and purification of recombinant proteins from
Escherichia coli
The C-subunit was expressed in E. coli and purified as
described (42). Full-length (1–379) constructs of either wild-
type, S101E, and S101Amutants of bRIa (in pRSET-Xa3 vector)
were expressed in BL21(DE3) cells and purified by cAMP affin-
ity chromatography in 20 mM MES (pH 6.5), 100 mM NaCl, 2
mM EGTA, 2 mM EDTA, and 5 mM DTT. RI proteins were
further purified on a gel filtration column using Superdex 200
and concentrated for purposes of biochemical assays using
Amicon centrifugal filters (EMDMillipore, Billerica, MA).
In vitro PKA RI phosphorylation by PKGI
To examine RI–PKAc holoenzyme phosphorylation by
PKGI, purified PKGI (43) was added to a 20-l reaction mix
containing 0.6g of wildtype RI–PKAc holoenzyme complex,
30 mMHEPES (pH 7.4), 10 mMMgCl2, 10 mM -glycerol phos-
phate, 100 mM ATP, 0.05 mCi of [-32P]ATP, and 1 M of the
indicated cyclic nucleotides. The reactions were incubated at
30 °C for 2 h. The reactions were terminated by adding 20 l of
2 SDS-PAGE loading buffer containing 100 mM EDTA fol-
lowed by boiling. Phosphate incorporation was determined by
SDS-PAGE/autoradiography. Densiometric analysis was per-
formed using ImageJ.
Cell culture: Growth, transfection, and treatments
HEK293T and mouse embryonic fibroblast (MEF) cells
were used throughout this study. Propagating cultures were
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grown in 10-cm dishes using Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum. MEF
cultures contained 1% penicillin/streptomycin, unless other-
wise stated.
Phosphorylation of RI in HEK293T cells
HEK293T cells were grown in Dulbecco’s modified Eagle’s
medium with 10% fetal bovine serum in a 37 °C incubator with
a 5% CO2 atmosphere. The day before transfection, the cells
were spit into a 6-well cluster dish such that the cells were
90–95% confluent at the time of transfection. The cells were
transfectedwith the indicated expression constructs with Lipo-
fectamine 2000 using conditions recommended by the manu-
facturer (Thermo Fisher). The next day, the medium was
removed, and 1 ml of phosphate-free media and 100 Ci of
32PO4was added to eachwell. The cells were incubated at 37 °C
for 2 h, and then 250M 8-CPT-cGMPwas added to the appro-
priate wells. The cells were incubated for an additional 2 h
at 37 °C, at which point the medium was removed, the cells
werewashed oncewith ice-cold PBS, and the cells were lysed on
the plate in PBS, 0.1%Nonidet P-40, 1 protease inhibitormix-
ture (Calbiochem, San Diego, CA), and 1HALT phosphatase
inhibitor (Cell Signaling Technology, Danvers, MA). Cleared
lysates were added to 20 l of anti-FLAG affinity gel and incu-
bated for 1 h at 4 °C with constant mixing. The beads were
washed and boiled in 30l of 1 SDS sample buffer, and phos-
phorylation was analyzed by SDS-PAGE/autoradiography. The
relative amount of immunoprecipitated FLAG-tagged RI was
determined by immunoblotting.
PepTag non-radioactive PKA phosphorylation assay
Assays using both cell lysates and recombinant proteins were
performed in a modified procedure from the manufacturer’s
directions. For cell-based experiments, MEF cell samples were
plated on 6-well dishes at passage 3. Transfections were con-
ducted using Lipofectamine 2000 (Thermo Fisher) as per the
manufacturer’s directions. For activity experiments, MEF cells
were serum-starved for 2 h before conducting 10 min of Fsk/
IBMX stress treatment (i.e. 20M forskolin and 100M IBMX).
10 l of cell lysate (of normalized protein concentration) was
added to 5 l each of “5 peptide,” “5 buffer,” and distilled
water for all reactions. The samples were mixed and incubated
at room temperature for 30 min and then heat-inactivated at
95 °C for 10 min. For recombinant protein experiments: RI
and PKAc proteins were incubated in situ at a 1.2:1 molar stoi-
chiometry within a 10-l volume (for RI(1–379) dimer pro-
tein, 5 l of 1.2 M R-subunit was added to 5 l of 2 M PKAc).
Then 5l each of 5peptide, 5buffer, and either 5mMcAMP
or distilledwaterwas added to start the reactions. Sampleswere
mixed and incubated at room temperature for 30 min and then
heat-inactivated at 95 °C for 10 min. For all experiments, phos-
phopeptides were separated by 0.8% agarose gel as per theman-
ufacturer’s directions. Densiometric analysis of gel images was
performed using ImageJ. Activity is expressed as the percentage
of phosphorylated peptide, calculated by the ratio of phosphor-
ylated peptide signal divided by total signal.
Immunoblotting
SDS-PAGE samples were prepared using 5 Laemmli buffer
(100 mM Tris-HCl, pH 7.0, 10% SDS, 50% glycerol, 0.01%
bromphenol blue). Protein concentrations were normalized
between samples, and then SDS-PAGE was performed using
NuPAGE 4–12% gradient gels (either 10-, 12-, or 15-well) in
MES running buffer (55 mM MES, 10 mM Tris-base, 1 mM
EDTA, 0.1% SDS). The gels were resolved at 150 V for 70 min
and then subsequently transferred to 0.45-m nitrocellulose
membranes (200 mA/blot for 60 min). The membranes were
blocked using 5% milk protein (or with 5% BSA for phosphob-
lots) in 1 PBS, 0.05% Tween for 60 min at room temperature,
and then primary antibodies were incubated overnight at 4 °C
in 1 PBS, 0.05% Tween 20 or 1 TBS, 0.1% Tween 20 at the
concentrations specified by the manufacturer. Densiometric
analysis was performed using ImageJ.
Co-immunoprecipitation
Expression vectors encoding HA-tagged PKAc and WT or
Ser101 mutant FLAG-tagged RI, or empty vector were trans-
fected into 293T cells using Lipofectamine 2000. After 20 h, the
cells were lysed in PBS, 0.1% Nonidet P-40 with 1 protease
inhibitor mixture. The lysates were cleared by centrifugation at
16,000 g for 10 min, and supernatants were incubated with
anti-FLAG M2 affinity gel for 1 h at 4 °C with constant mix-
ing. The beads were washed three times with PBS, 0.1% Non-
idet P-40, proteins were eluted by boiling in 2 Laemmli
buffer, and bound proteins were analyzed by SDS-polyacryl-
amide gel electrophoresis followed by immunoblotting. For
some experiments, 500 M Kemptide was added during the
immunoprecipitations.
PCA using fragmented RLuc
Plasmid constructs of PKAc taggedwith F1 fragment (PKAc-
F1) and RI tagged with F2 fragment (RI-F2) were generated
previously (27). S101E and S101A mutations of RI were
introduced into RI-F2 by site-directed mutagenesis via
QuikChange PCR as per the manufacturer’s instructions
(Stratagene). PKAc-F1 and either WT, S101E, or S101A ver-
sions of RI-F2 plasmids were co-transfected into HEK293T
cells, and bioluminescence signal was compared under basal
conditions, as well as with 15 min of 10 nM isoproterenol
stimulus.
LiReC fluorescence polarization assay
Use of the LiReC assay has been described previously (28). All
reactions were conducted in assay buffer (50 mM MOPS, pH
7.0, 35 mM NaCl, 10 mM MgCl2, 1 mM ATP, 2 mM DTT, and
0.005%TritonX-100).End-pointfluorescencepolarizationmea-
surements were performed using a GENios Pro plate-reader
spectrometer (Tecan, Mannendorf, Switzerland), configured
with 485-nm excitation and 535-nm emission filters and using
optimal gain settings. Concentrations of proteins, [5/6-FAM]-
IP20, and cAMP for each experimentalmethod are listed below:
for cAMP response experiments, 12.0 nM PKA catalytic sub-
unit, 14.4 nM PKA regulatory subunit bRI (91–379) or bRI
(1-379) (based on monomer concentration), 2.0 nM [5/6-
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FAM]-IP20, 1 nM-1 M cAMP (dissolved in 1 buffer without
ATP or DTT); and for R-subunit inhibition response experi-
ments, 10.0 nM PKA catalytic subunit, 1 nM-1 M PKA regula-
tory subunit bRI(91–379) or bRI(1–379) (based on mono-
mer concentration), 1.67 nM [5/6-FAM]-IP20.
Statistics
All activity, immunoblot, and PCA data are presented as
means  S.D., and all fluorescence polarization assay data are
presented as means  S.E. GraphPad Prism 4 software
(GraphPad Software, Inc., San Diego, CA) was used for all
statistical analysis. Statistical analyses were performed by
unpaired Student’s t test of planned comparisons.
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